Home > Resources > Webcasts > On-Demand Webcasts >

2017 Pharmacy Drug Coding and Billing Strategies

Learn valuable information on the JW modifier, APC packaging of observation, off-campus PBD, and more that could impact you this year.

Price: $240.00


Description Biographies

Resolve to eliminate the coding and billing mistakes that routinely sabotage pharmacy revenues and compliance. With help from MedLearn Publishing, you will be equipped with easy-to-understand and reliable explanations of the substantial changes this year, including the JW modifier, APC packaging of observation, off-campus PBD, new drug codes, and more. Take a look at the webcasts agenda:

  • Medicare Payment for Outpatient Drugs — for 2017, Part B drug prices decreased by 0.4 percent.
  • Change of Policy for Pass-Through Status — CMS revised policy on the transitional pass-through payment period.
  • OPPS Update to Change and Status Indicators — revised status indicator E and other updates.
  • Drug Updates — including the packaging threshold payments for non-pass-through and biologicals, change to drugs with pass-through status, biosimilar drug guidance, compound drug code J7999 clarification.
  • Prolonged Infusion — Billing the provider?
  • JW Modifier (Transmittal 3538) — effective January 1, 2017.
  • Billing of Waste — JW modifier, correct units of Herceptin (Trastuzumab), and single-dose vs. single-use vial.
  • 2017 OPPS HCPCS Updates and Changes
  • Review of Reporting Essentials
    • Drug descriptors
    • HCPCS codes
    • Pricing
    • Billing units
    • Innovation models
    • VBP proposed Part B payment model
    • Prescribing of Opiate/Opioid drugs
    • Comprehensive APC (C-APC)
    • APC packaging of observation
    • Site-neutral payment for Off-Campus PBDs
    • Documentation requirements for drugs
    • National Drug Codes (NDC reporting)
    • Self-administered drugs
  • Audit Findings — including the latest CMS news, 2017 OIG Work Plan, and the Recovery Audit Contractors (RACs).
  • Hot Topics — price gouging and orphan drugs.